COVID-19 researcher has ties to Geisel School of Medicine
Jason S. McLellan, associate professor of molecular biosciences, left, and graduate student Daniel Wrapp, right, work in the McLellan Lab at The University of Texas at Austin on Monday, Feb. 17, 2020. While at the Geisel School of Medicine s Department of Biochemistry and Cell Biology, McLellen was amongst those doing research that led to a COVID-19 vaccine. (The University of Texas at Austin - Vivian Abagiu)
Jason McLellan, associate professor of molecular biosciences, and others work in the lab at The University of Texas at Austin on Monday, Feb. 17, 2020. While at the Geisel School of Medicine s Department of Biochemistry and Cell Biology, McLellen was amongst those doing research that led to a COVID-19 vaccine. (The University of Texas at Austin - Vivian Abagiu)
Groundwork for Covid-19 vaccine laid at Dartmouth
Geisel research being employed by Pfizer/BioNTech
January 7, 2021
Structural biologist Jason McLellan and his colleagues at Geisel and two other prominent labs conducted groundbreaking research on the coronavirus spike protein, the major surface protein that this type of virus uses to bind to human cells and invade them.
Discoveries originating in a basic science lab at Geisel School of Medicine’s Department of Biochemistry and Cell Biology are being used in the newly approved Covid-19 vaccine from the Pfizer/BioNTech partnership.
Beginning in 2016, structural biologist Jason McLellan and his colleagues at Geisel and two other prominent labs, conducted groundbreaking research on the coronavirus spike protein, the major surface protein that this type of virus uses to bind to human cells and invade them.
Discoveries originating in a basic science lab at Geisel School of Medicine’s Department of Biochemistry and Cell Biology are being used in the newly approved COVID-19 vaccine from the Pfizer/BioNTech partnership.
Beginning in 2016, structural biologist Jason McLellan, PhD, and his colleagues at Geisel and two other prominent labs, conducted groundbreaking research on the coronavirus spike protein, the major surface protein that this type of virus uses to bind to human cells and invade them.
McLellan and his team designed a special form of the spike protein that makes it more likely to be effective as a vaccine antigen, a part of the virus that can be used to stimulate antibody production in advance, and thus help the body fight off infection.